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Clinical practice guidelines (CPGs) are “systematically de-
veloped statements to assist practitioner and patient decisions 
for specific clinical circumstances” [1]. They are collections of 
statements (recommendations) to be used in order to change 
or support current clinical practice [2]. CPGs, as well as sy-
stematic reviews and economic or decision analyses, constitute 
so-called secondary publications, which synthesize data from 
primary research on a particular, defined clinical problem. 
The main difference between CPGs and other publications, 
both primary and secondary, is that CPGs include formal re-
commendations on practical application of the available infor-
mation. To be evidence based, CPG should rely on on valid 
systematic reviews of current evidence.
The number of such publications is rising constantly. In 
2006, almost 700 new or updated CPGs were registered in 
MEDLINE database. Their significance for clinical care is also 
rising as clinicians increasingly use them to guide their deci-
sions concerning patient management, being convinced (or at 
least hoping) that they will not err, will help their patients, or 
that at least they will do no harm.
One may ask, however, if there is a risk that relying on cur-
rently available CPGs will not result in optimal patient care? 
We believe that such a risk exists and that all clinicians using 
CPGs should be aware of it. The danger of error exists at each 
stage of the guidelines development process: from choosing 
the scope of a guideline, through selection of authors, deciding 
what type of evidence and outcomes to consider, interpreting 
the balance between benefits and downsides of alternative ma-
nagement strategies, to the formulation of recommendations. 
Furthermore, guidelines may be incorrectly interpreted or in-
appropriately used.
How to assess the quality of clinical practice 
guidelines?
Let us start with the methodology of CPG development. 
Although the number of guidelines is constantly increasing, 
their quality and resulting validity may still be far from op-
timal. CPGs must fulfill certain criteria of quality. An inter-
national group of methodologists and CPG developers have 
proposed such criteria in an AGREE instrument [3,4]. Each 
of the twenty three criteria, grouped in six domains (tab. 1) 
is assessed on a four point scale. A summary score suggests to 
what degree a guideline is valid, reliable, and worth applying 
in clinical practice.
The first domain deals with a scope of the guideline, pre-
cision of clinical questions addressed, and description of the 
target population of patients. The second domain evaluates 
how well the given guideline reflects views and preferences of 
prospective users. This is because different management deci-
sions may be made on the basis of the same objective evidence, 
depending on cultural, religious, and legal determinants, or 
personal values and preferences. Hence, guideline panels sho-
uld include representatives of all stakeholders, including pa-
tients. The third domain assesses the process of selection and 
summarising of the evidence (this part of CPG development is 
relatively objective, verifiable, and reproducible) and the pro-
cess of formulating and updating recommendations (which is 
relatively subjective). This is a critical issue in the evaluation 
of CPG validity. A full review of this process exceeds the sco-
pe of this article. However, we would like to point out the 
growing worldwide acceptance of the GRADE system [5–10], 
which was created to make the process of CPG development 
and formulating recommendations more systematic and uni-
form. The fourth domain of the AGREE instrument evaluates 
user-friendliness of the guidelines. The greatest importance is 
attached to specificity and unequivocality of the recommen-
dations. The fifth domain comprises criteria that allow to as-
sess if the CPG could be used in daily clinical practice, if its 
economic consequences have been considered, and if criteria 
for monitoring and audit are included. The sixth domain eva-
luates the probability that the authors’ conflict of interest may 
have influenced the recommendations. This is possible at the 
level of the organization financially supporting the develop-
ment of the CPG or through financial relationships between 
authors and the medical industry. One of the limitations of the 
AGREE Instrument is the lack of formal rules for interpreta-
tion of the derived scores. Nevertheless, the instrument helps 
to identify limitations of the CPGs.
The development of new practice guidelines is extremely 
time and effort-consuming, costly, organizationally difficult 
and requires specific knowledge (not only in clinical aspects 
but also in the methodology of the CPG development). It also 
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requires that the authors remain neutral as much as possible. 
If these conditions are not fulfilled, it is suggested that exist-
ing valid CPGs should be adapted. Such approach is recom-
mended e.g. by the Council of Europe [11]. As an example we 
point out Polish guidelines on prophylaxis and treatment of 
venous thromboembolic disease, developed in 2002 [12] and 
updated in 2005 [13] through a rigorous process of adapta-
tion of original CPGs issued by the American College of Chest 
Physicians [14], while taking into account local factors. These 
adapted guidelines have been endorsed by many professional 
and scientific societies in Poland.
Do we get the guidelines right?
If we want to use the guidelines in everyday practice, 
we must be able to interpret the recommendations correct-
ly. First of all, we must know if a specific recommendation 
applies to our patient (or a specific group of patients) as their 
liberal extrapolation may not be appropriate. Another limi-
tation of most CPGs is that they apply to “average” patients 
and frequently do not take into account existing comorbidities 
although they are common in clinical practice. It is also crucial 
to understand the authors’ confidence in their recommenda-
tions. The present-day variety of different systems of grading 
strength of recommendations makes this judgment even more 
difficult. If we are not sure as to the strength of recommenda-
tions and quality of evidence on which recommendations are 
based, we risk making wrong decisions. It is noteworthy that 
less rigorously developed guidelines usually comprise stronger 
recommendations.
Are clinical practice guidelines appropriately 
used?
CPGs may be intentionally or unintentionally used for 
a purpose that they are not intended for.
One of the aforementioned guideline validity criteria is the 
inclusion of specific means to monitor adherence to guideli-
nes and the effects of following the recommendations. These 
evaluate mainly clinicians’ adherence to the guideline, since 
the impact of guideline implementation on patient outcomes 
is much more difficult to assess. Thus, one may monitor effects 
of CPG implementation measuring the change in behaviour 
(e.g. one may check the percentage of patients with diabetic 
nephropathy who received a renin-angiotension system blo-
cker). This system of quality control however is occasionally 
used to assess the performance of individual physicians [15] 
and – depending on the results – determine their salary. Such 
an approach may lead to the neglect of patient preferences 
while making decisions to use a diagnostic or therapeutic stra-
tegy recommended in the guideline, when the patient either 
cannot or does not want to take the recommended medication 
or agree to an invasive diagnostic procedure.
There is also a risk of indiscriminate implementation of 
all recommended interventions, which may create significant 
Table. The AGREE Instrument
Scope and purpose 
  1.  The overall objective(s) of the guideline is (are) specifically 
described. 
  2.  The clinical question(s) covered by the guideline is (are) 
specifically described
  3.  The patients to whom the guideline is meant to apply are 
specifically described
Stakeholder involvement 
  4.  The guideline development group includes individuals from all 
the relevant professional groups 
  5. The patients’ views and preferences have been sought 
  6. The target users of the guideline are clearly defined
  7. The guideline has been piloted among target users
Rigour of development 
  8. Systematic methods were used to search for evidence
  9. The criteria for selecting the evidence are clearly described
10.  The methods for formulating the recommendations are clearly 
described
11.  The health benefits, side effects and risks have been considered 
in formulating the recommendations
12.  There is an explicit link between the recommendations and the 
supporting evidence
13.  The guideline has been external reviewed by experts prior to its 
publication
14. A procedure for updating the guideline is provided
Clarity and presentation
15. The recommendations are specific and unambiguous
16.  The different options for management of the condition are 
clearly presented
17. Key recommendations are easily identifiable
18. The guideline is supported with tools for application
Applicability
19.  The potential organisational barriers in applying the 
recommendations have been discussed
20.  The potential cost implications of applying the 
recommendations have been considered
21.  The guidelines presents key review criteria for monitoring and/
or audit purposes
Editorial independence
22. The guideline is editorially independent from the funding body
23.  Conflicts of interest of guideline development members have 
been recorded
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problems for patients suffering from several coexisting disea-
ses, especially for the elderly. This was well illustrated by Boyd 
and colleagues, who considered a hypothetical situation of ha-
ving to manage according to current guidelines a 79-year-old 
woman with chronic obstructive pulmonary disease, type 2 
diabetes, osteoporosis, hypertension, and osteoarthritis [16]. 
It turned out that such a patient should be taking twelve dif-
ferent medications and on top of this follow an appropriate 
diet. One can easily imagine the burden associated with such 
a management, not to mention its cost, and the risk of harmful 
drug interactions.
It is also quite likely that an elderly patient will not neces-
sarily gain expected benefits from all prescribed medications 
and that the quality of her life may actually worsen due to 
a complex medication scheme. It is also quite probable that 
given a large number of pills the patient will simply not follow 
the physician’s recommendations.
Clinical practice guidelines are sometimes also used for 
marketing of medical products. It has to be stressed that it 
is not only important if authors of CPGs actually did recom-
mend certain option based on a biased judgement but also if 
a rational person could get an impression that it may have 
happened. We will illustrate this problem with a promotional 
strategy of a new drug used to treat severe sepsis and septic 
shock – a recombinant human activated protein C (rhAPC) 
[17]. This example shows several problems occurring at the 
junction of guideline development and marketing efforts of 
the pharmaceutical industry. In the United States, rhAPC was 
introduced in 2001 to treat sepsis and septic shock on the basis 
of one phase III trial, even though half of the FDA panel that 
assessed the application for drug voted for a requirement of 
one more randomized trial to confirm benefits. In 2002, in 
order to increase administration of rhAPC, the manufacturer 
hired a public relation company. Its task was to develop and 
help to implement a multi-stage marketing strategy. One of 
the main instruments of this strategy became the CPG deve-
loped by an international group of experts that strongly re-
commended the use of rhAPC [18]. The authors of a recent 
editorial in the New England Journal of Medicine describing 
the above story pointed out that the development of these cli-
nical practice guidelines was sponsored in over 90% by the 
manufacturer of rhAPC and that several of the panel mem-
bers were financially connected with this company, receiving 
research or conference grants, lecture honoraria, etc [17]. This 
obviously does not imply that authors were not objective and 
that recommendations were consciously biased, nevertheless 
it calls for more cautious approach to these recommendations 
and provides argument for those who disagree with them. In 
subsequent studies, although in slightly different populations, 
the efficacy of rhAPC was not confirmed and an increased risk 
of bleeding was observed. Those findings have not yet been 
reflected in CPGs (although an update is expected soon).
Another aspect of the rhAPC promotion strategy was to 
introduce its use (or at least consideration of it) to sepsis and 
septic shock management algorithms in hospitals. Again, 
the financial contributions of the drug manufacturer to the 
development and implementation of these algorithms might 
have led to an impression of restricting physicians’ freedom of 
independent judgment about the available data and of drug 
promotion.
The story described above is not unique as regards the in-
teractions between industry and clinical medicine. The parti-
cular attention it received was due to the concerns elicited by 
a single sponsor and one very expensive drug.
It is possible that a planned repetition of the first trial, 
which showed significant benefit, may satisfy those who be-
lieve that rhAPC is a life-saving drug the cost of which is si-
milar or even smaller than that of other widely accepted in-
terventions. Time will show. In the meantime, it is worth to 
remember that even an impression of the conflict of interests 
may determine the fate of guidelines, i.e. their uptake and im-
plementation in everyday practice.
How to use practice guidelines?
What are the prerequisites for CPGs to bring the expected 
clinical benefits? First, CPGs must address clinically important 
questions. Second, all recommendations should be supported 
by systematically collected and appraised evidence, and clearly 
connected to this evidence, even though they are always to 
a degree subjective. The strength of recommendations should 
be stated, reflecting the confidence of the guideline panel that 
adherence to these recommendations will do more good than 
harm. Third, users of CPGs must be able to assess their vali-
dity and properly interpret recommendations. Fourth, and the 
most important, CPGs should not replace clinical judgement 
and should not be used as rigid rules [19,20]. Let us remem-
ber that CPGs constitute just one, even though important and 
useful, of the elements to be considered in clinical decision 
making. Ignoring other elements, especially specific clinical 
circumstances or values and preferences of a patient may lead 
to loss of expected benefits from using CPGs.
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